Theratechnologies Inc
TSX:TH

Watchlist Manager
Theratechnologies Inc Logo
Theratechnologies Inc
TSX:TH
Watchlist
Price: 4.47 CAD -4.89%
Market Cap: 205.5m CAD

Theratechnologies Inc
Pre-Tax Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Theratechnologies Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Theratechnologies Inc
TSX:TH
Pre-Tax Income
-$6.8m
CAGR 3-Years
49%
CAGR 5-Years
18%
CAGR 10-Years
1%
Repare Therapeutics Inc
NASDAQ:RPTX
Pre-Tax Income
-$108.8m
CAGR 3-Years
7%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Pre-Tax Income
$79.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Pre-Tax Income
-$309.7m
CAGR 3-Years
-40%
CAGR 5-Years
-62%
CAGR 10-Years
-40%
Willow Biosciences Inc
TSX:WLLW
Pre-Tax Income
-CA$4.1m
CAGR 3-Years
N/A
CAGR 5-Years
38%
CAGR 10-Years
N/A
Spectral Medical Inc
TSX:EDT
Pre-Tax Income
-CA$21.4m
CAGR 3-Years
-28%
CAGR 5-Years
-21%
CAGR 10-Years
-9%
No Stocks Found

Theratechnologies Inc
Glance View

Market Cap
205.5m CAD
Industry
Biotechnology

Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 87 full-time employees. The firm has two approved products: EGRIFTA SV in the United States, and Trogarzo in the United States, the European Union and the United Kingdom. EGRIFTA SV (tesamorelin for injection) is developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Trogarzo (ibalizumab-uiyk) is developed for HIV treatment. The treatment is infused every two weeks. The company is a new class of antiretrovirals (ARV), and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs. The firm markets its prescription products in the United States, Europe and Canada. Its research pipeline is focused on specialized therapies addressing unmet medical needs in HIV, oncology and non-alcoholic steatohepatitis (NASH).

TH Intrinsic Value
5.54 CAD
Undervaluation 19%
Intrinsic Value
Price

See Also

What is Theratechnologies Inc's Pre-Tax Income?
Pre-Tax Income
-6.8m USD

Based on the financial report for May 31, 2025, Theratechnologies Inc's Pre-Tax Income amounts to -6.8m USD.

What is Theratechnologies Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
1%

Over the last year, the Pre-Tax Income growth was -4%. The average annual Pre-Tax Income growth rates for Theratechnologies Inc have been 49% over the past three years , 18% over the past five years , and 1% over the past ten years .

Back to Top